
Welcome to Utah!

Utah's wide-open skies and our lakes; core principles such as faith, knowledge, freedom, optimism, and tradition



famous snow canyon represents
Southern Utah's majestic
landscape. The color symbolizes
perseverance, and nods to the red
strips of the United States flag, but
on the Utah flag the value of the
red color is slightly warmer in hue.



Utah's new state flag. Utah Legislature

A gold rim stands for prosperity, while the hexagon shape – among nature's **strongest** shapes – cradles the beehive and represents unity and the strength of Utah's people.



The beehive represents Utah's history and a sense of community, plus "Industry," our state's slogan.

At the foundation of the beehive is a five-pointed star, which represents **hope** and 1896, the year Utah achieved statehood and became the 45th star on America's flag, a sign of our loyalty to our country.

Thank you to our prize donors!



















Advancing CMV education and testing: reflections on a decade of progress

Stephanie Browning McVicar, Au.D., CCC-A
Early Hearing Detection and Intervention (EHDI) Programs
Manager



Learning objectives



health.utah.gov/CMV

Learning objective 1: Describe the evolution and impact of Utah's CMV testing program over the last 10 years

Learning objective 2: Cite advancements in legislation and progress around CMV both inside and outside the United States


Learning objective 3: Identify the central role of parents in advocacy and education

The Utah EHDI programs


Early Hearing
Detection and
Intervention (EHDI)



Congenital
Cytomegalovirus
(CMV) Public
Health Initiative



Children's Hearing Aid Program (CHAP)



Let's go back in time...





Enrolled Copy H.B. 81

CYTOMEGALOVIRUS PUBLIC HEALTH INITIATIVE
2013 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Ronda Rudd Menlove
Senate Sponsor: Curtis S. Bramble
LONG TITLE
General Description:
This bill amends the Utah Health Code and directs the Department of Health to
establish a public education program regarding the impacts and dangers of congenital
cytomegalovirus (CMV) infection and the methods of prevention of CMV infection.
Highlighted Provisions:
This bill:
 directs the Department of Health to create a public education program to inform
pregnant women and women who may become pregnant about the occurrence of
CMV, the transmission of CMV, the birth defects that CMV can cause, methods of
diagnosis, and available preventative measures;
 requires the Department of Health to provide this information to:
 licensed child care programs and their employees;
 health care facilities licensed pursuant to Title 26, Chapter 21, the Health Care
Facility Licensing and Inspection Act;
 child care programs administered by educational institutions regulated by the
boards of education of this state, private education institutions that provide
education in lieu of that provided by the public education system, or by
parochial education institutions;
 child care programs administered by public or private institutions of higher
education, if the care is provided in connection with a course of study or
program, relating to the education or study of children, that is provided to
students of the institution of higher education;

FISCAL NOTE

H.B. 81 1st Sub. (Buff)

SHORT TITLE: Cytomegalovirus Public Health Initiative

SPONSOR: Menlove, R. (Menlove, R. Sub.)

2013 GENERAL SESSION

STATE GOVERNMENT (UCA 36-12-13(2)(b))

This bill costs the Department of Health \$30,800 ongoing General Fund beginning in FY 2014 and \$4,000 one-time General Fund in FY 2013 for a 0.5 FTE educator and educational materials.

STATE BUDGET DETAIL TABLE	FY 2013	FY 2014	FY 2015
Revenue	\$0	\$0	\$0
Expenditure:			
General Fund	\$0	\$30,800	\$30,800
General Fund, One-Time	\$4,000	\$0	\$0
Total Expenditure	\$4,000	\$30,800	\$30,800
Net Impact, All Funds (RevExp.)	(\$4,000)	(\$30,800)	(\$30,800)
Net Impact, General/Education Funds	(\$4,000)	(\$30,800)	(\$30,800)

LOCAL GOVERNMENTS (UCA 36-12-13(2)(c))

Enactment of this bill likely will not result in direct, measurable costs for local governments.

DIRECT EXPENDITURES BY UTAH RESIDENTS AND BUSINESSES (UCA 36-12-13(2)(d))


Enactment of this bill likely will not result in direct, measurable expenditures by Utah residents or businesses.

PERFORMANCE NOTE (JR 4-2-404): Not Required

State of Utah, Office of the Legislative Fiscal Analyst



2014 CMV Public Health & Policy Conference



Utah CMV law

26-10-10 UCA, "Cytomegalovirus (CMV) Public Education and Testing"

 UDOH* establish and conduct a public education program to inform pregnant women and women who may become pregnant about CMV (incidence, transmission, birth defects, diagnostic methods, preventative measures)

 Provide information to: child care providers, school nurses, health educators, health care providers, religious organizations offering children's programs as part of worship services

*Beginning 7/1/2022 UDOH=DHHS (Department of Health and Human Services) Recode: 26B-7-105



Cytomegalovirus (CMV)



What is CMV?

CMV is a common virus that people of all ages can get. People who have it can pass it to others through their body fluids. Most healthy people don't feel sick when they have CMV.

How CMV affects the Circle

When CMV occurs during a woman's pregnancy, the baby can become infected before birth. CMV can cause hearing

loss, vision loss, seizures, cerebral palsy and other disabilities in the baby.

Protect the Circle

While Pregnant:

- Try to kiss young children on the forehead rather than the lips.
- Try not to put things in your mouth that have just been in a child's mouth.





Protect the Circle

Passing down
knowledge of
Cytomegalovirus
(CMV)

Growing your family is an honor and blessing. The mother, father, and all ancestors have a role in preparing for a new child.



Cytomegalovirus



What women NEED TO KNOW about CMV

For Women Who are Pregnant or Planning to Become Pregnant

Hearing screening is simple and painless

Otoacoustic Emissions (OAEs) use an earphone to play sound into the ear canal and record an echo response from the hearing organ, called the cochlea.



Hearing loss is invisible



The **Automated Auditory Brainstem Response** (**AABR**) plays sound into the ear and uses electrodes placed on the baby's head to detect a response from the hearing nerve and brain.

What can my baby hear during pregnancy?

By **7 weeks** gestation your baby's ear structures are beginning to develop

By **25 weeks** gestation your baby will begin to hear and respond to sounds

Your speech is one of the predominant uterine sounds that your baby hears. They are already learning language in the womb!

CMV and hearing loss

Cytomegalovirus or CMV is a common virus that infects people of all ages; however, when it occurs during pregnancy, the baby can become infected potentially causing damage to their brain, vision, and/or hearing. CMV is transmitted through direct contact with body fluids, such as saliva or urine.

If you're pregnant or planning a pregnancy, the best way to protect your baby from CMV is to protect yourself.

For more information about CMV: health.utah.gov/cmv nationalcmv.org



Is my baby at risk for hearing loss?

The following are risk factors that may increase the risk for hearing loss:

- Stays in the hospital longer than 5 days
- Mom had an infection such as herpes, CMV, toxoplasmosis, or rubella during pregnancy
- A family member was diagnosed with hearing loss as an infant or young child

Babies at risk can pass a hearing screening at birth but need more testing later. Newborn hearing screening can also miss a mild hearing loss.

Educational materials

Cytomegalovirus (CMV) PCR Testing

CMV PCR testing for Utah Public Health Initiative (H.B.81 - UCA 26-10-10)

- Many laboratories currently offer PCR-based CMV testing. Testing can be performed on saliva
 or urine. As of July 1st, 2013, ARUP Laboratories is the only local facility that has a validated test
 for salive.
- Each primary care provider should submit specimens through their normal laboratory testing
 mechanism. If the laboratory service does not normally use ARUP as the referring laboratory
 and this test is desired, please specify the testing location as ARUP, and include test name and
 test code listed below. All laboratories have the ability to forward specimens to ARUP through
 their channels.
- Pricing will vary depending on the laboratory and the specific hospital contract. Primary care
 providers will need to consult their affiliated hospitals or reference laboratories to obtain pricing
 information.
- . The CPT code for CMV detection (qualitative) by PCR is 87496, and is covered by Medicaid.

Information on ARUP's CMV PCR tests

Specimen type	Saliva	
ARUP Test Name	Cytomegalovirus by Qualitative PCR, Saliva	
Short Name	CMVPCR SAL	
ARUP Test Code	2008555	
Specimen Collection	Collect and submit saliva in ORACollect OC-100 kit (ARUP supply #49295)	
Stability of Specimen	Ambient: 7 days; Refrigerated: 7 days; Frozen: 3 months	
Reported	1-3 days	
NOTE:	If a saliva specimen is received in a collection device different from the specified device (#49295), specimen will still be tested but patient report will include a non-validated specimen disclaimer.	

Specimen type	Urine	
ARUP Test Name	Cytomegalovirus by PCR	
Short Name	CMV PCR	
ARUP Test Code	0060040	
Specimen Collection	Collect and submit 1 mL urine. Sterile urine container, no preservative.	
Stability of Specimen	Ambient: 8 hrs; Refrigerated: 72 hrs; Frozen 3 months	
Reported	1-3 days	



Early Hearing Detection & Intervention (EHDI)

Cytomegalovirus (CMV) Public Health Initiative

FOR OBSTETRICAL HEALTH CARE PROVIDERS

it should I tell my patients about CMV?

About 40% of women (40 of every 100) who become infected with CMV for the first time during a pregnancy will pass the infection to their fetus.

About 1 in 150 children is born with congenital CMV infection. In Utah, this equates to one child per day.

Congenital CMV infection is a known, but very rare, cause of pregnancy loss.

About 1 of every 5 children born with congenital CMV infection (1 in 750 children overall) will develop permanent problems (such as hearing loss or developmental disabilities) due to the infection.

Congenital CMV infections can only be prevented by preventing CMV infection in pregnant women. There is no available vaccine for preventing CMV. However, pregnant women can take steps that may reduce their exposure to CMV.

Talking Points:

- If you're pregnant or planning a pregnancy, the best way to protect your baby from CMV is to protect yourself.
 - Wash your hands often with soap and water for 15-20 seconds, especially after
 - changing diapers
 - · feeding a young child
 - · wiping a young child's nose or drool
 - handling children's toys
 - . Don't share food, drinks, or eating utensils with a child.
 - Do not put a child's pacifier in your mouth.
 - Do not share a toothbrush with a young child.
 - Use soap and water or a disinfectant to clean toys, countertops, and other surfaces that may have a child's saliva or urine on them.
 - · Avoid contact with a child's saliva when kissing or snuggling.

The Utah Department of Health CMV Core Facts could be provided to patients as a source of basic information about CMV infection and prevention. There is also a brochure entitled, "CMV What Women NEED TO KNOW", that can be given to your patients.

1





1 out of 5 children born with Cytomegalovirus (CMV) will have permanent disabilities. Know the facts. Protect your baby.

1 de cada 5 niños que nacen con Citomegalovirus (CMV) tendrá discapacidades permanentes. Conocer los hechos. Proteger a su bebé.





Let's go back in time...

Bill Sponsor:



Rep. Menlove, Ronda Rudd

Floor Sponsor:



Sen. Bramble, Curtis S.



H.B. 81 Enrolled Copy

30	 child care programs administered at public schools by organizations other than
31	the public schools if the care is provided under contract with the public schools
32	or on school properties or if the public schools accept responsibility and
33	oversight for the care provided by the organizations;
34	 child care programs provided by organizations that qualify for tax exempt status
35	under Section 501(c)(3) of the Internal Revenue Code or that are provided
36	pursuant to a written agreement with a municipality or county;
37	 child care programs provided at residential support programs that are licensed
38	by the Department of Human Services;
39	 school nurses;
40	 health educators;
41	 health care providers offering care to pregnant women and infants; and
42	 religious, ecclesiastical, or denominational organizations offering children's
43	programs as a component of worship services;
44	 directs medical practitioners to test infants, who fail the newborn hearing screening
45	test(s), for CMV and inform the parents of those infants about the possible birth
46	defects that CMV can cause and the available treatment methods;
47	 directs the Department of Health to notify medical practitioners of the CMV testing
48	requirements; and
49	 grants rulemaking authority to the Department of Health.
50	Money Appropriated in this Bill:
51	None
52	Other Special Clauses:
53	None
54	Utah Code Sections Affected:

ENACTS:

26-10-10, Utah Code Annotated 1953

Utah CMV law

26-10-10 UCA, "Cytomegalovirus (CMV) Public Education and **Testing**"

If a newborn infant fails the newborn hearing screening test(s)...

 Medical Practitioner shall: Test the newborn infant for CMV before 21 days of age... unless the parent objects;

 And provide to the parents information re: birth defects caused by congenital CMV and available methods of treatment

Utah CMV law

26-10-10 UCA, "Cytomegalovirus (CMV) Public Education and **Testing**" (continued)

UDOH shall:

Provide information to the family and the medical practitioner (if known)
information re: the testing requirements when providing results indicating that an
infant has failed the newborn hearing screening test(s).



STATE OF UTAH DEPARTMENT OF HEALTH

Cytomegalovirus

Utah Chapter of the

Message From t



The new Gun campa campa right. F Preven Store y

public trigger locks, safes, and ammuni We will do this in an apolitical ar reach a broad audience.

We hope to accomplish our goal local organizations. The Univers Relations organization, *Absolute* website and logo free-of-charge. be able to educate the communi professionals, legislators, gun or ranges and legislators about the

lovirus

Congenital CMV and Hearing Loss



What Parer

STATE OF UTAH DEPARTMENT OF HEALTH

Citomegalovirus

CMV Congénito y la Pérdida de Audición



Lo que los Padres Necesitan Saber

pients of the Marty Palmer

evement Award & Hemond When I Grow Up Award

CMV Public Health Initiative

Health Services Available to

dical Home Portal

plause, Applause

d allergies? If so, we're here to

acco dependence be done in


Utah CMV rule

R398-4-3. Clarification of when a newborn fails a hearing screen.

• The newborn **must fail both hearing screens**, the initial hearing screen routinely done at birth **and** the subsequent follow up screen, **OR**


 if/when the initial failed hearing screen is obtained after 14 days of age the medical practitioner is required to test for CMV

OR (3) The newborn must be referred for CMV testing if they have failed an inpatient screening and have not completed or been able to complete the outpatient screening before 14 days of age.




'Other' includes CSF and IgG/I

lution of specimens



Utah Newborn Hearing Screening



Utah Newborn Hearing Screening

Utah CMV rule





R398-4-4. Special populations of newborns.

 In special populations of newborns where newborn hearing screening(s) cannot be accomplished prior to 21 days of age, testing for CMV is left to the discretion of the medical practitioner(s) caring for the newborn.

 Special populations of newborns may include, but are not limited to, premature or medically fragile newborns or newborns receiving ongoing medical care.









High Risk Testing Protocol had widespread adoption by hospitals (Intermountain) in Utah in the autumn of 2019


CMV testing by target reason



Data from 09/2019 - 06/2022, though 2021 is incomplete (Jan - May, Dec data only for 2021)



For all cCMV cases since 09/2019



Utah CMV rule

R398-4-5. Reporting Requirements

Medical practitioners are required to submit results of the CMV testing to UDOH
for each newborn under their care who is referred for CMV testing within 10 days
of receiving results.





Process maps

Utah Newborn Hearing Screening & CMV Testing Protocol

INFANT FAILS **INPATIENT** NEWBORN HEARING SCREENING (NBHS)

Hospital NBHS Program notifies family their infant failed hearing screen and schedules outpatient rescreen to take place prior to 14 days of age emphasizing importance of completing this appointment at the scheduled time

Hospital NBHS Program obtains complete primary care provider (PCP) information from family and enters it in infant's HiTTrack record. If complete information is not in the physician database "drop down" menu , it can be added/updated by contacting Utah Early Hearing Detection & Intervention (EHDI) Hi*Track Data Coordinator at (801) 584-8216

Hospital NBHS Program advises PCP of initial screen failure using the "Notification of Failed 1st Newborn Hearing Screening" form or other mutually agreed upon method of notification. The method of notification must be documented in HiTrack (Recommended Action: Notify PCP of Failed Screening) & Hospital Program Summary

INFANT FAILS 2ND (OUTPATIENT) HEARING SCREENING

Hospital NBHS Program immediately notifies PCP of the follow-up hearing screening failure: 1) via fax using the "Cytomegalovirus & Auditory Brainstem Response Testing Orders" form or Notification of Failed Second Newborn Hearing Screening form, 2) phone call, or 3) other preferred method of communication. The method of notification must be documented in HiTrack (Recommended Action: Referral for CMY PCR)

Hospital NBHS Program will give "Cytomegalovirus & Auditory Brainstem Response Testing Orders" form to the family to take to the lab for CNV testing. **ICentra users to follow Intermountain Healthcare's electronic ordering protocol

TESTING OCCURS PRIOR TO 21 DAYS OF AGE

Schedule diagnostic ABR prior to family leaving

Lab will send results to EHDI & PCP. For positive CMV results, EHDI Medical Director will consult with PCP. PCP to inform parents of CMV results

Reporting



Hospital Births:



Referral and Testing for CONGENITAL Cytomegalovirus (CMV)

(801) 273-6600

 Complete CMV & ABR Testing Order Form* and send copy to the infant's primary care provider if they either failed two hearing screenings (both the inpatient and the outpatient screen) OR failed their first hearing screening at age 14 days or older

CMV & ABR Testing Order Form looks like this:



2. A sample will need to be collected **BEFORE** the infant is **21 days** old:




Acceptable

OR



Saliva**





NOT



Blood Unacceptable

3. Assist family to the hospital lab





6. When lab results are received, please fax results to (801) 536-0492.



*CMV & ABR Testing Order Form can be found in the Providers tab at health.utah.gov/CMV.

For more information visit health.utah.gov/CMV

Improving lab test receipt and amending rules

- (7) Laboratory results reportable by electronic reporters are as follows:
- (a) In addition to laboratory results set forth in Subsections R386-702-3(2) through R386-702-3(6), entities reporting electronically shall include the following laboratory results or laboratory results that provide presumptive evidence of the following communicable diseases:
 - (i) influenza virus;
 - (ii) norovirus infection;

R398-2-6. Reporting to Utah Department of Health....

R398-4-5. Reporting Requirements.

- (1) Medical practitioners are required to submit results of the CMV testing to the Department for each newborn under their care who is referred for CMV testing within ten days of receiving results.
- (2) Laboratories testing for the presence of congenital CMV must submit results of the CMV testing to the Department within ten days of receiving results.
 - (3) The Department may make referrals to help coordinate care and provide resources for the affected child and their family

(vii) nepainis 11,

- (viii) hepatitis B, including viral loads;
- (ix) hepatitis C, including viral loads;
- (x) HIV, including viral loads and confirmatory tests;

d



Cytomegalovirus & Auditory Brainstem Response Testing Orders

NOTE: NO ACTION REQUIRED BY PROVIDER, order has been placed

Parent: Your baby failed their newborn hearing screening (NBHS) and Utah law requires lab testing be completed for a common virus, Cytomegalovirus (CMV), which can be associated with hearing loss. CMV testing is painless, requiring a urine sample (preferred) or a saliva sample. *A saliva sample should be obtained at least 2 hours after breastfeeding. * It is vital that this CMV lab test is done before your baby is 21 days of age. Your baby also requires a more detailed hearing test known as ABR (Auditory Brainstem Response), which should be scheduled as soon as possible. Results of both the CMV and ABR tests will be reported to your primary care provider (PCP) and the State Early Hearing Detection and Intervention (EHDI) Program which is responsible for the newborn hearing screening and CMV test mandates.

nfant's Full Name:	Birthdate:
Mother's Full Name:	Phone #(s):
Primary Care Provider (PCP):	
PCP Phone #:	
NBHS Facility:	
	specific questions, contact NBHS facility**

CPT code 92652 Diagnosis Code H91.90 (neonatal hearing loss) Diagnostic ABR testing should include BOTH click and frequency-specific stimuli, bilaterally.

2. CMV Qualitative PCR Lab Testing Order

Diagnosis Code H91.90 (neonatal hearing loss) CPT code 87496* *If unavailable, 87497 would be acceptable

Urine is the preferred method: if unable obtain then use Saliva (Blood is NOT acceptable)

Urine (bagged specimen)

Test name: Cytomegalovirus by Qualitative PCR (CMVPCR)

Specimen Collection: collect and submit 1 ml

Urine in sterile container, no preservative.

Stability of specimen: Ambient: 24 hrs; Refrigerated: 24 hrs; Frozen: 3 months

Reported: 1-3 days

Saliva (cheek swab with ORACollect OC-100 kits) **Should be obtained 2 hours after breastfeeding**

Test name: Cytomegalovirus by Qualitative PCR, Saliva (CMVPCR SAL)

ARUP Test Code: 2008555 Intermountain Test Code: CMVSLV

Specimen Collection: Collect and submit saliva in ORACollect OC-100 kit

To obtain ORACollect OC-100 kits: ARUP Client Services: 801-583-2787 Intermountain Client Services: 801-507-2110 Stability of specimen: Ambient: 7 days; Refrigerated: 7 days; Frozen: 3 months

Reported: 1-3 days

RESULTS MUST BE FAXED TO: PRIMARY CARE PROVIDER listed above & EHDI PROGRAM listed below.

FAX# 801-536-0492

ORDERING PHYSICIAN: Michelle Hofmann, MD, MPH, MHCDS, FAAP, EHDI Medical Director


NPI#1760550628 LIC#282612-1205

Revised 6.7.23


OUESTIONS?? Please call 801-273-6600

Utah CMV testing order


- Educate families regarding CMV testing requirement
- Order CMV testing *before 21 days* of age
- Only use *Urine or Saliva specimen*
- Remind mothers to not breastfeed their baby for **two hours** prior to saliva swab
- Results come to UDOH directly from the lab



2018-2021



Lab testing data collection



*Not just hearingtargeted testing

Reasons for missed tests

2018 & 2019

- 155 eligible babies did not receive CMV testing
 - 34 (22%) passed a second OP screen (or first OP screen if IP screen was after 14 days)
 - Half of this group were out-of-hospital births
 - o **31 (20%)** had a normal hearing diagnostic ABR


2020 & 2021

- 138 eligible babies did not receive CMV testing
 - 55 (40%) passed a second OP screen (or first OP screen if IP screen was after 14 days)
 - More than half of this group were out-of-hospital births
 - 32 (23%) had a normal hearing diagnostic ABR


Reasons for Missed Tests - Additional

- was not collected at next appointment (reason unknown). EHDI CMV coordinator called parents and referred them to ARUP to get testing done. Saliva swab was collected, but <u>unable to be processed</u>. Family was exasperated and refused further testing at that point.
 - **2019** Family had to leave after OP appointment, so they didn't get CMV testing done. EHDI CMV coordinator called both the pediatrician and the family to encourage CMV testing to be completed. Older sibling of the child failed their NBHS and turned out "fine" so the *family felt it was unnecessary* to follow up with either CMV or diagnostic hearing testing.
 - 2020 Family did not follow up with CMV testing due to <u>COVID-19 concerns</u>.
 - 2021 Baby was <u>medically fragile</u> and prone to UTIs. Hospital doctors had not mentioned CMV test to the family, so they were skeptical of the state health department reaching out. EHDI CMV Coordinator attempted to follow up multiple times with no responses.

Hospital variability



Non-compliance?




CMV report cards


Early Hearing Detection & Intervention (EHDI) NEWBORN HEARING SCREENING PERFORMANCE REPORT



Comments: Great job screening and rescreening all of your infants. Your referral rate is high so be sure you aren't screening too quickly after birth. One infant did not receive follow-up audiological testing and then moved out of state. Per mom's report, this family was also unaware of the need for CMV testing, however did have it completed after outreach from the EHDI team. One CMV eligible infant refused CMV testing, and the two other eligible infants were tested after 21 days. If the CMV tests had been positive, it would have been difficult to differentiate between congenital vs postnatal (acquired) CMV infection. Please be sure you are assisting families with receiving CMV testing on eligible infants. All of your 2022 infants received their hearing screening before 1 month of age, meeting the 1 month milestone. Of those with diagnostic testing, both received it prior to 3 months of age. And the one infant with permanent hearing loss was enrolled in Early Intervention prior to 6 months of age. Thank you to your staff for always being responsive when further hearing information is needed. We appreciate you all. Thank you for all you do for the health of infants in Utah!


National EHDI milestones are: 100% of infants screened by 1 month of age, 90% diagnosed before 3 months of age, and 90% enrolled in Early Intervention (EI) before 6 months of age.





While out of hospital births only comprise about **1/10th** of all CMV-eligible babies, they make up over **1/3rd** of all CMV-eligible babies whose parents refuse testing.

Out of Hospital Births (OOHB) CMV data




Early Hearing Detection and Intervention Program

Out of Hospital Births

Shannon Wnek, AuD, CCC-A, EHDI Audiology & Compliance Coordinator
Holley Ezzell, BS, EHDI Follow-up Coordinator
Krysta Badger, BS, EHDI Data Coordinator
Max Sidesinger, MPH, EHDI Epidemiologist, CMV Data Coordinator
Jenny Pedersen, AuD, CCC-A, Hearing Aid Programs Coordinator



Hospital performance




The advocacy power of parents






CMV legislation: July 2013



Utah CMV Council



The advocacy power of parents



Janelle Greenlee Stop CMV 2003



Farah Armstrong Maddie's Mission 2014



Sara Menlove Doutré



Annie Culley



Abigail Wright






Utah CMV Council 2014




Kristen Hutchinson Spytek


CMV legislation: November 2015




CMV legislation: May 2017



CMV legislation: January 2020



CMV legislation: October 2023



*CMV screening has to be offered after failing NBHS

**Universal CMV screening!

OH: June is designated cCMV Awareness Month to increase public awareness and encourage testing of NB

NJ: public awareness campaign and Universal CMV screening once added to the RUSP (Recommended Universal Screening Panel)

ME: 2017 – committee established to investigate universal CMV screening. 2022 – passed education and hearing-targeted screening.

CT: 2023 – amended current hearing-targeted legislation to be universal in 2025

The power of parents

- Minnesota 2021 "The Vivian Act"
- Kentucky 2022 "Bella Dawn Streeval Law"
- New York 2022 "Elizabeth's Law"
- Louisiana 2023 "Journie's Law"



Elizabeth Saunders died at 16 years old from a seizure after she contracted congenital cytomegalovirus, or CMV, as a newborn, leading to severe health issues throughout her life. Her mother, Lisa Saunders, has advocated to prevent more health issues from CMV after her daughters death. Provided: Lisa Saunders



Leah Henrikson and her kids Vivian and Asher address reporters Wednesday. The Vivian Act was named after Leah's daughter, who was born with congenial cytomegalovirus. Minnesota officials announced the state will be the first in the nation screening all newborns for CDMV. J. Michelle Wiley IMPN News

Loss to law; Adair Co. mother raises awareness for virus that took young daughter's life



An Adair County mother is taking the tragic death of her daughter, and using it to raise awareness of a deadly and common virus not many people know about



Steve, Miranda, and Journie Bailey Rep. Horton, and Karen Young

HB 643

Enacts
"Journie's Law"
to require
cytomegalovirus
(CMV) testing for
children who fail
their newborn
hearing
screening.

CMV testing: Canada Infants Manitoba: Yukon Whitehorse Territories. British Columbia. Alberta. Manitoba. Edmonton Que bec Ontario CANADA - Political Bruin swick A line rta Prosinceterriors Toronto JK. OttawaNatonal capital Regina, Prostnoialiterritorial capital.

Newborn Screening **Ontario**:

- May, 2018 -July 29,2019: CMV screening offered if infant did not pass NBHS
- After July 29,2019: CMV screening offered for all

In 2020, bill introduced for universal newborn CMV Screening. Some targeted screening is conducted.

Saskatchewan: universal newborn CMV screening

in 2022

Map source: Wikipedia

Father pushing Manitoba to follow Ontario, Saskatchewan in screening for CMV






Article External Article Medical Expert Insights

Position Statement on Universal Congenital Cytomegalovirus Screening in Canadian Newborns

The Canadian Infant Hearing Task Force, in collaboration with Speech-Language & Audiology Canada, the Canadian...

May 18, 2022



CMV testing: Canada



Alberta: government invested \$6 million to expand the Alberta Newborn Screening Program to include 5 new conditions, including cCMV in August, 2023

CALGARY News

Parents applaud Alberta's commitment to expand newborn screening to include congenital CMV



The Craig Family

CMV testing: Europe



The Craig Family

CMV position statements

2017

Congenital cytomegalovirus infection in pregnancy and the (1) (1) neonate: consensus recommendations for prevention. diagnosis, and therapy

William D Rawlinson, Suresh B Boppana, Karen B Fowler, David W Kimberlin, Tiziana Lazzarotta, Sophie Alain, Kate Daly, Sara Doutré, Laura Gibson, Michelle L. Giles, Ianelle Greenlee, Stuart T. Hamilton, Gail I. Harrison, Lisa Hui, Chervl A. Iones, Pamela Palasanthiran, Mark R. Schleiss Antonia W Shand Wendu Luan Zuulen

Congenital cytomegalovirus is the most frequent, yet under-recognised, infectious cause of newborn malformation in Lancetinfect Dis 2017; developed countries. Despite its clinical and public health importance, questions remain regarding the best diagnostic 47:e177-88 methods for identifying maternal and neonatal infection, and regarding optimal prevention and therapeutic strategies Published Online for infected mothers and neonates. The absence of guidelines impairs global efforts to decrease the effect of congenital cytomegalovirus. Data in the literature suggest that congenital cytomegalovirus infection remains a research priority, but 51/073-3999(17)30143-3 data are yet to be translated into clinical practice. An informal International Congenital Cytomegalovirus Recommendations Group was convened in 2015 to address these questions and to provide recommendations for prevention, diagnosis, and SMLSMirot treatment. On the basis of consensus discussions and a review of the literature, we do not support universal screening of Wales Hospital Sydney, NSW. mothers and the routine use of cytomegalovirus immunoglobulin for prophylaxis or treatment of infected mothers.

| Australia | Prophylaxis | P However, treatment guidelines for infected neonates were recommended. Consideration must be given to universal neonatal screening for cytomegalovirus to facilitate early detection and intervention for sensorineural hearing loss and wiyan Living https://school of developmental delay, where appropriate. The group agreed that education and prevention strategies for mothers were Medical Sciences beneficial, and that recommendations will need continual updating as further data become available.

prevented since the introduction of maternal screening part of routine antenntal care, 500 for infectious diseases during pregnancy, and since of reproductive age. In stark contrast congenital cytomegalovirus infection remains largely unrecognised congenital cytomegalovirus now being the major infectious cause of sensorineural hearing loss and developed countries,2 and second only to cerebral palsy has been reported as 0.2% to 2.0% (average of 0.64%) of pregnancies.3 Many factors contribute to congenital limited awareness of clinicians and parents about infection during pregnancy, low levels of routine testing of neonates at risk, the absence of maternal or neonatal screening programmes, the limited efficacy and toxicity of current treatments, and the absence of licensed vaccines. In part, because of these limitations, congenital cytomegalovirus and preventive measures for acquiring consist of, were also addressed. cytomegalovirus during pregnancy are not routinely or consistently discussed with pregnant women or women attempting conception. However, with evidence for on cytomegalovirus prevention, diagnosis, efficacy of preventive actions, efficacy of early intervention for children with sensorineural hearing loss,3 evolving antiviral treatments, and recent availability of candidate vaccines for pregnant women and neonates.6 there is an emerging consensus that more attention

researchers, and communities. In some states of the Biomolecular Science Many adverse fetal and neonatal outcomes have been USA, legislation requires cytomegalovirus education as (ProfWDRawlinson) and

To assist with clinical care, an informal International MD, University of New South the institution of routine rubella vaccination of women Congenital Cytomegalovirus Recommendations Group Wales, NSW, Australia, was convened as part of the 5th International Congenital Department of Pediatrics & Cytomegalovirus conference on April 19, 2015, to review Microbiology (Prof S B Boogana M.D. in the developed and developing world. This is despite and grade available evidence, and to draft recommendations profit Found 1990) and that could be used to guide congenital cytomegalovirus Division of Pediatric Infe diagnosis, prevention, and therapy. The International Diseases neurodevelopmental abnormalities in infants born in Gongenital Cytomegalovirus Recommendations Group (PetDW GenberinMD), University of Alabama at addressed whether pregnant women should be screened to Birmingham, AL, USA; in all causes of serious malformation in many parts of aid diagnosis of maternal cytomegalovirus infection, and Operative Unit of Ginical the world. The prevalence of congenital cytomegalovirus also addressed methods for diagnosis of maternal or fetal Microbiology, Laboratory of cytomegalovirus infection. Suggestions about who should Virology, Polyclinic be educated about congenital cytomegalovirus infections, Department of Specialised cytomegalovirus mortality and morbidity, including the and preventive measures for maternal cytomegalovirus Soperimental and Diagnostic infection, were considered. Whether cytomegalovirus Medicine, University of hyperimmunoglobulin or antiviral therapy could be used Bologna, Bologna, Italy routinely to prevent or treat congenital cytomegalovirus National Reference Center for infection during pregnancy was discussed. Neonatal Cytomogalovirus, CHU screening and the important questions of whether to treat Limoges, Laboratoire de infected neonates, and what form this therapy should Université de Limoges.

Methods to provide global recommendations

Expert clinicians, opinion leaders for congenital cyto- (5Doutré,) Greenlee); megalovirus, researchers with expertise in congenital Departments of Medicine and cytomegalovirus infection, and representatives of the Infectious Diseases and congenital cytomegalovirus community from Europe, the Immunology, University of must be directed to this infection by clinicians. USA and Australia were identified and invited to a MassachusettsMedical School

(ProfW D Raylinson

W I van Zuvlen), School of

School of Women's and Chik

(Prof S Alain PhD): Congenital

NSW Australia (K Daly):

National Cytomegaloviru

ESPID REPORTS AND REVIEWS

CONTENTS

Congenital Cytomegalovirus **EDITORIAL BOARD**

Editor: Delane Shinoadia

David Burgner (Melbourne, Kow-Tong Chen (Tainan, Taiwan) Luisa Galli (Florence, Italy) Stone Conham (Melhoume

(Rahia Receil) Ville Peltola (Turku, Finland) Emmanuel Roilides (Thessaloniki George Syrogiannopoulos (Larissa, Greece) Tobias Tenenbaum (Mannhein, Germany) Marc Tebruegge (Southampton, UK) Marceline Tutu van Furth (Amsterdam,

2017

Congenital Cytomegalovirus

A European Expert Consensus Statement on Diagnosis and Management

Suzanne E. Luck, MBChB, MD, *†† Jantien W. Wieringa, MD, § Daniel Blázquez-Gamero, MD, PhD, ¶ Philipp Henneke, MD, || Katharina Schuster, MD, || Karina Butler, MB, BCh, FRCPI, ** Maria Grazia Capretti, MD, PhD, †† Maria José Cilleruelo, PhD.11 Nigel Curtis, MA, MBBS, DCH, DTM&H, MRCP, FRCPCH, PhD.88 Francesca Garofoli, PhD. ## Paul Heath, MB BS, FRCPCH. * Elias Iosifidis, MD, MSc, PhD. || || Nigel Klein, BSc. MBBS, PhD, *** Giuseppina Lombardi, MD, ††† Hermione Lvall, BSc Hons, MBChB, MD, FRCPCH, ††† Tea Nieminen, MD, PhD, §§§ Dasja Pajkrt, MD, PhD, MBA, ¶¶¶ Vassiliki Papaevangelou, MD, PhD, || || || Klara Posfay-Barbe, MD, MS, **** Laura Puhakka, MD, §§ Emmanuel Roilides, MD, PhD, FIDSA, FAAM, IIII Pablo Rojo, MD PhD, Jesús Saavedra-Lozano, MD, PhD, †††† Teshri Shah, MSc, ‡‡‡ Mike Sharland, FRCPCH,* Harri Saxen, MD, PhD, 888 and Ann C,TM Vossen, MD, PhD, 2222 on Behalf of the ESPID Congenital CMV Group Meeting, Leipzig 2015

Congenital cytomegalovirus (cCMV) is the most common congenital infection

Accepted for publication August 31, 2017 From the *Paediatric Infectious Diseases Research Group, St George's University, London, United Kingdom; †Centre for Virology, University College Medical School, London; ‡Kingston Hospital NHS Foundation Trust, London, United Kingdom; §The Hague Medical Center (HMC), Department of Pediatrics and Sophia Children's hospital, Frasmus Infectious Diseases; Pediatric Infectious Diseases Unit, Hospital Universitario 12 de Octubre, Uni-versidad Complutense, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain; [Center for Chronic Immunodeficiency and Center for Pediat-rics and Adolescent Medicine, Medical Center and Faculty of Medicine, University of Freiburg, Ger-many, **Our Lady's Children's Hospital Crumlin. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 0891-3668/17/3612-1205

Key Words: congenital CMV, investigation, in the developed world. Reported prevalence varies between cohorts but is approximately 7 per 1000 births.1 About half of cytomegalovirus (CMV)-infected babies with clinically detectable disease at birth are destined to have cally detectable disease at birth, they are also significant impairments in their development, and cCMV infection is implicated in approxi-

> UCD School of Medicine and Health Sciences, Dub-88Podiatric Infectious Diseases, Children's Hoslin, Ireland; ††Department of Obstetrical, Gynaepital, University of Helsinki and Helsinki Univercological and Paediatric Sciences, Operative Unit sity Hospital, Finland; MDepartment of Pediatric of Neonatology, Polyclinic St. Orsola-Malpighi, Infectious Diseases Emma Children's Hosnital University of Bologna, Bologna, Italy: ##Padiatric Academic Medical Center, Amsterdam, The Neth-Infectious Diseases, Hospital Universitario Puerta erlands; || || || National and Kapodistrian University of Athens, Greece: ****Children's Hospital of Geneva. de Hierro Majadahonda, Madrid, Spain; §§Depart-University Hospitals of Geneva, Switzerland; ment of Paediatrics. The University of Melbourne & Murdoch Children's Research Institute, Royal ††††Pediatric Infectious Diseases Unit, Gregorio Marañón Hospital, Madrid, Spain; and ‡‡‡‡Depart-Children's Hospital Melbourne, Parkville, Australia: ment of Medical Microbiology, Leiden University SINICII and Noonatal Unit Fondazione IRCCS Medical Center, Leiden, The Netherlands Policlinico S. Matteo, Pavia, Italy: IllInfectious Dis-Dr Luck has recently provided consultancy services eases Unit, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Thessaloniki, Greece; ***Great Ormond Street Children's Hospital, London, and the Institute

The authors have no funding or conflicts of interest

MBChB, MD, Paediatric Infectious Diseases Research Group, St George's University, Jenner Wing, Level 2, Room 2 216F, Mail Point J2C, Lon-

mately 25% of all children with sensorineural

hearing loss (SNHL),12 Meta-analysis shows

that although long-term sequelae, especially

SNHL, are more common in those with clini-

found in 13% of those without clinical features

attributable to CMV on initial examination.1

†††NICU and Neonatal Unit, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy, ###Imperial College NHS Healthcare, London, United Kingdom; The ESPID Reports and Reviews of Pediatric Infectious Disease Journal series topics, authors and contents are chosen and approved independently by the Editorial Board of ESPID.

of Child Health, UCL, London, United Kingdom;

www.pidj.com | 1205

American Academy of Audiology Position Statement on Early Identification of Cytomegalovirus in Newborns

Maggie Kettler, AuD (Chair)¹ Angela Shoup, PhD² Shelley Moats, AuD³ Wendy Steuerwald, AuD⁴ Sarah Jones, AuD⁵ Stacy Claycomb Stiell, AuD⁶ Jenni Chappetto, BA⁷

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio Callier Center for Communication Disorders, The University of Texas

at Dallas, Dallas, Texas

3 Norton Children's Medical Croup, Louisville, Kentucky ⁴ Phoenix Children's Hospital, Phoenix, Arizona

⁵ Georgia Mobile Audiology, Atlanta, Georgia

⁶ University of Colorado Hospital, Aurora, Colorado University of Cincinnati, Cincinnati, Ohio

LAm Acad Audiol

Abstract

Keywords ► CMV

- ► cCMV
- congenital
- ➤ cytomegalovirus
- ► hearing loss
- ► hearing screening newborn
- newborn screening

The American Academy of Audiology recommends early identification of congenital cytomegalovirus (cCMV) through screening to allow for appropriate early diagnosis, intervention, and monitoring for congenital, progressive, and delayed-onset hearing loss in infants with cCMV.

Address for correspondence editor@audiology.org

Early identification of cCMV is a valuable component in the diagnostic evaluation of infants with sensorineural hearing loss. The Academy recognizes the important role audiologists serve as clinical care providers and educators and advocates for early identification and audiological management of infants with cCMV.

Introduction and Rationale

Congenital cytomegalovirus (cCMV) is the leading cause of nongenetic childhood sensorineural hearing loss (SNHL). Universal newborn hearing screening (UNHS) is the standard of care in hospitals nationwide, and some infants with

Approved by the Academy Board of Directors on March 7, 2023.

Abbreviations

cytomegalovirus congenital cytomegalovirus hearing targeted

sensorineural hearing loss UNHS universal newborn hearing screening

hearing thresholds outside the typical range identified through UNHS will also have cCMV. Due to the time-sensitive nature of cCMV testing (must be completed by 21 days of age) and high loss to follow-up rates for hearing screening, cCMV screening should be completed at the birth hospital before discharge, although screening can be conducted post discharge, Models for early identification of cCMV include universal cCMV screening, hearing-targeted cCMV (HTcCMV) screening, and expanded targeted cCMV screening. Universal cCMV screening is defined as cytomegalovirus (CMV) polymerase chain reaction or culture testing by blood. saliva, or urine screening of all babies for the CMV infection at birth. HT-cCMV screening programs test infants who do not pass two or more hearing screenings. Expanded targeted cCMV screening is testing that targets a range of symptoms

© 2023. American Academy of Audiology, All rights reserved. Thieme Medical Publishers, Inc., 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

DOL https://doi.org/ 10.1055/s-0043-1768036. ISSN 1050-0545.

www.thelancet.com/infection Vol 17 June 2017

The Pediatric Infectious Disease Journal • Volume 36, Number 12, December 2017

Copyright @ 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

RUSP application



2021

ACHDNC Form for Nomination of a Condition for Inclusion in the Uniform Screening Panel

DATE: September 30th, 2021

NAME OF NOMINATOR AND ORGANIZATION	INDICATE AFFILIATION
(include professional degrees)	(i.e., Health Professional, Subject Matter Expert,
	Researcher, Clinician, Advocate, etc.)
National CMV Foundation	Advocacy Organization

	Co-Sponsoring Organizations Indicate Affiliation	
	(include professional degrees)	(i.e., Health Professional, Subject Matter Expert, Researcher, Clinician, Advocate, etc.)
N	lational CMVF RUSP Nomination Team	Advocates, Public Health Professionals, Researchers,
(8	see enclosure for membership list)	Subject Matter Experts, Legislator, and Clinicians (see
- 1	-	enclosure for individual affiliations)

*Note: Please reference each statement/answer with the corresponding reference number listed in Section III – Key References.

SECTION I - CONDITION INFORMATION AND TREATMENT

SECTION I, PART A

Condition	Statement
Nominated Condition	Congenital Cytomegalovirus (cCMV) Infection
Type of Disorder	Congenital viral infection
Screening Method	The presence of cytomegalovirus (CMV) can be detected at birth using nucleic acid amplification tests (NAAT), which include polymerase chain reaction (PCR) or isothermalamplification (e.g., loop-mediated isothermal amplification or 'LAMP'). Saliva is the preferred specimen for congenital CMV (cCMV) screening, with urine used for confirmatory testing ¹⁻⁴ .
Gene	NA
Locus	Include CinVar link if applicable. NA
OMIM or other names for condition	Include Genetics Home Reference link if applicable. NA

Page 3

If you have any questions about the additional information requested or when you are ready to submit an updated package, please contact me at achdnc@hrsa.gov.

Thank you for your nomination of cCMV for inclusion on the RUSP. I look forward to hearing from you soon.

Sincerely yours,

/s/

Ned Calonge, MD, MPH Chairperson

ATTACHMENT: Summary of Nomination Requirements and Key Considerations

Cc: Soohyun Kim, MPH
Acting Designated Federal Official
Health Resources and Services Administration

CMV position statements





23-ID-02

Committee: Infectious Disease

Title: Standardized Surveillance Case Definitions for Congenital Cytomegalovirus (cCMV) Infection and Disease

Check this box if this position statement is an update to an existing standardized surveillance case definition and include the most recent position statement number here: N/A.

- . This position statement creates standardized case definitions for cCMV infection and disease.
- · Standardized case definitions for cCMV infection and disease are needed because multiple jurisdictions in the United States are conducting cCMV screening and surveillance activities but are using various methods and inclusion criteria for case ascertainment, reporting, and classification. As more jurisdictions pass legislation for newborn screening for cCMV, standardized case definitions for cCMV infection and disease can be used to understand the epidemiology of cCMV and compare trends across the United States.
- Case ascertainment criteria include laboratory criteria (the detection of CMV in neonatal urine, saliva. whole blood, or cerebrospinal fluid specimens, in amniotic fluid specimens, or umbilical cord or autopsy specimens), vital records criteria (infant death certificates), and healthcare records criteria (e.g., using ICD-10 diagnostic codes).
- Case classification criteria include clinical and laboratory criteria.
- Case classifications include confirmed cCMV infection, confirmed cCMV disease, and probable cCMV

I. Statement of the Problem

Cytomegalovirus (CMV) infection during pregnancy can cause stillbirth, infant death, and a myriad of birth defects. 1-3 In the United States (U.S.), approximately 1 in 200 babies is born with congenital CMV (cCMV) infection; one out of 5 of these babies will present with clinical signs of cCMV disease in the neonatal period and/or have long-term health conditions.4 cCMV is the most common infectious cause of developmental disabilities and non-genetic sensorineural hearing loss (SNHL) in U.S. children.5-8 Nonetheless, the burden of cCMV disease is not fully understood.9-11

Surveillance of cCMV in the U.S. is complicated by several factors. First, most newborns with cCMV infection have no clinical signs at birth and, without universal cCMV screening, are not identified. 12,13 Second, neonatal clinical signs of cCMV disease are nonspecific and may be attributed to other conditions. 14 Third, postnatal CMV infection is common among infants, and a reliable diagnosis of cCMV infection or disease may not be possible unless specimens are collected within the first three weeks of life.15 Finally, not all newborns with a laboratory diagnosis of cCMV infection receive a diagnostic code that would allow cases to be ascertained through a review of administrative data.16

II. Background and Justification

cCMV infection is responsible for an estimated 5-10% of cases of prelingual hearing loss among children less than 2 years of age, and an estimated 15-20% of moderate to profound bilateral SNHL among all U.S. children.7,17 A substantial proportion of cCMV-related SNHL cases occur in children with cCMV infection who do not have apparent clinical signs at birth, including those who pass the newborn hearing screen.18 Early identification and timely and appropriate intervention services are critical for improving developmental outcomes of deaf or hard-of-hearing children. 19-22 Consequently, the Joint Committee on Infant Hearing recommends that all infants who test positive for cCMV receive periodic audiologic monitoring beginning no later than three months of age to allow for the provision of appropriate amplification, early intervention, and family support. 23 Jurisdictional programs that monitor children with Council of State and Territorial Epidemiologists

23-ID-02

cCMV surveillance grants



SET-NET:

Surveillance for Emerging Threats to Pregnant People and Babies Network 8/1/22 – 7/31/24

Iowa, LA County, Minnesota, New Jersey, New York, Utah,

CDC-RFA-DD-23-0003 "Pregnant People-Infant Linked Longitudinal Surveillance" 9/30/2023 - 9/29/2027

Illinois, New Jersey, Virginia UMN, Baylor

CMV vaccines

CMV Vaccine Development: How Close

Are We?

WE ARE GETTING CLOSER!!

NIAID Conference Center

CMV RNA vaccine

VSV vectored gB/VLP CMV vaccine program

CMV polyepitope-gB bivalent vaccine

CMV-MVA-Triplex vaccine

CMV vectored vaccine program

nanoparticle CMV vaccine program

mRNA-1647 vaccine program

dense body vaccine candidate

Replication-defective human CMV vaccine



Monday:

UT/CDC | Establishing standardized case definitions for cCMV infection and disease in the US | Room 6613 | 2:30 – 2:55 PM

Tuesday:

UT | An analysis of cCMV cases identified in Utah, 2013-2023 | Flynn Room | 1:30-2:30

UT | An overview of the CSTE cCMV position statement's impact on Utah's case classification | Room 6619 | 2:45 – 3:10 PM








Jacinda Merrill

Utah Sessions



I know it seems hard
sometimes, but remember
one thing. Through every
dark night, there's a
bright day after that. So
no matter how hard it
gets, stick your chest out,
keep ya head up and
handle it.

Tupac Shakur

positivityblog.com

We are all in this together!

Thank you! smcvicar@utah.gov 801-273-6600